The Planning Commission is back in the news. The latest round of poverty levels that have been disclosed have created another debate in the country. Once more, people are stunned at the meager rate of Rs 28 that has been defined as the poverty line. Even though I addressed some apprehensions in an earlier post, this time around the issue seems to be more about myths, perceptions and lack of...
More »SEARCH RESULT
Cut in NREGA allocation may hit FMCG firms-Meghna Maiti
The reduced allocation to the UPA government’s flagship rural programme NREGA could see revenue growth in the FMCG sector falter. Consumer staples firms have been relying on rural demand growth to bolster their top line but the reduced allocation to the Mahatma Gandhi National Rural Employment Guarantee Scheme (NREGA) for the financial year 2012-13 could see growth in FMCG sales in rural areas being crimped feel industry experts. Finance minister Pranab...
More »ADB calls for another Green Revolution
-The Hindu Food subsidies for poorest will help them cope: ADB A hike in the cost of food staples like rice and wheat could push tens of millions more people into extreme poverty in the South Asian region including India, says an Asian Development Bank (ADB) report. The Manila-based lending agency, in its report “Food Price Escalation in South Asia – A Serious and Growing Concern” released on Monday, however, said that food...
More »Facts, not outrage
-The Business Standard Public discussion on falling poverty hits a new low The Lok Sabha was adjourned for a short duration on Wednesday following an uproar over the government’s latest figures for poverty. This follows widespread public outrage at those figures. A dispassionate observer of this discussion may be led to conclude that either poverty has risen dramatically or the government has somehow fudged the figures inexcusably and obviously. Elsewhere perhaps,...
More »India patent bypass delivers life-saving blow against cancer by Raja Murthy
India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...
More »